The shares in Torrent Prescribed drugs Ltd. fell probably the most in eight months after analysts stated the valuation of its acquisition of Curatio Healthcare (I) Pvt. is pricey, though they count on the deal to extend the drugmaker’s presence in dermatology and increase its income from the phase.
Torrent Pharma has agreed to totally purchase the sunscreen-cream-to-baby-soap maker for a money consideration of Rs 2,000 crore, in line with its September 27 change submitting.
The acquisition is anticipated to deliver Torrent Pharma to the tenth place within the derma phase from the present 21, the submitting states. It should additionally make the pharma firm the second largest in beauty dermatology.
The transaction is anticipated to be accomplished inside a month.
Shares in Torrent Pharma fell as a lot as 5.5% on the day — probably the most since Jan. 27 — and had been buying and selling 3% decrease as of 1 p.m. 11:40 a.m. Wednesday.
Of the 32 analysts monitoring the corporate, 22 have a “purchase” ranking, six counsel a “maintain” and 4 suggest a “promote,” in line with Bloomberg information. The typical of the 12-month consensus value goal implies an upside of 12.9%.